Month: March 2024

Minerals Technologies Announces First Quarter 2024 Conference Call

Written by Customer Service on March 29, 2024. Posted in Public Companies.

NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) — Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it will release results for its first quarter ended March 31, 2024, on Thursday, April 25, 2024, after the market close. The Company will host a conference call on Friday, April 26, 2024, at 11:00 a.m. Eastern Time to discuss these results. The conference call will be webcast and can be accessed at Minerals Technologies’ website at https://investors.mineralstech.com/quarterly-results-conference-calls About Minerals Technologies Inc.New York-based Minerals Technologies Inc. (MTI) is a leading, technology-driven specialty minerals company that develops, produces, and markets a broad range of mineral and mineral-based products, related systems, and services. MTI serves globally a wide range of consumer and...

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

– Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 – – Ongoing combination phase 2 dose expansion in MSS CRC increased to over 50 patients, including initiation of a new, unprecedented 20 mg/kg loading dose regimen, with data anticipated during 2024 – – Validation of SAFEbody masking technology by Exelixis and Sanofi showcases versatility of platform across modalities including antibody-drug conjugates, bi-specific and monoclonal antibodies – – Cash balance of approximately US$110 million funds streamlined operations into 2026 – SAN DIEGO and...

Professional Diversity Network, Inc. Announces Financial Results for the Quarter and Fiscal Year Ended December 31, 2023

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

CHICAGO, March 29, 2024 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (NASDAQ: IPDN), (“IPDN” or the “Company”), a global developer and operator of online and in-person networks that provides access to networking, training, educational and employment opportunities for diverse and specialized individuals, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a challenging year for PDN, considering the optimism we had as we closed out fiscal 2022. The early 2023 downturn in the economy and reduced hiring in industries that are personnel heavy caused us to look to restructure ourselves internally and alter our marketing strategies,” said Adam He, CEO of Professional Diversity Network. “We acquired Expo Experts at the beginning of fiscal 2023 and increased our interest...

FSI ANNOUNCES FULL YEAR, 2023 FINANCIAL RESULTS

Written by Customer Service on March 29, 2024. Posted in Public Companies.

A Conference call is scheduled for Wednesday April 3rd, 2024, 11:00am Eastern Time See dial in number below VICTORIA, BRITISH COLUMBIA, March 29, 2024 (GLOBE NEWSWIRE) — FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today the Company announces financial results for full year ended December 31, 2023. Mr. Daniel B. O’Brien, CEO, states, “2023 was a difficult year to navigate. Residual inventory at high base and shipping costs collided with our ability to set prices to customers. Given these circumstances, the results were reasonable...

C-Bond Systems to File its Form 10-K on April 1, 2024, and Hold Conference Call to Discuss its Financial Results on April 3, 2024

Written by Customer Service on March 29, 2024. Posted in Public Companies.

The Company will issue a press release on April 2, 2024, with its financial results for 2023 SAN ANTONIO, March 29, 2024 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, announced today that it will file its Form 10-K on April 1, 2024, and issue a press release on April 2, 2024 with its financial results. The Company will hold a conference call at 9:30 am ET on April 3, 2024, to discuss those results in more detail and hold a question-and-answer session. The Company will also review its preliminary outlook for its financial results for the first quarter ended March 31, 2024, for which the Company previously stated it expects to report revenues of more than $1 million. Call InformationTo access the live call, please dial 832-917-1510...

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting 2024 Phase 2 randomized trial in PDAC is underway with enrollment expected to complete in the fourth quarter of 2024 ELI-002 7P initial clinical trial data expected in the second quarter of 2024 Private placement with gross proceeds of $6.0 million closed in March 2024BOSTON, March 29, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights. “2023...

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

— Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 —— Exploring opportunities to expand KPI-012 into additional corneal indications —— Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 — ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. “In 2023, we focused on clinical execution, advancing...

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program. We completed enrollment and randomization for the NAVIGATE Phase 2b/3 trial in 2023, and belapectin has consistently shown an encouraging safety profile, which was determined by our independent Data and Safety Monitoring Board on multiple reviews. We are pleased with the recent addition of Khurram Jamil, M.D., to our team. Dr. Jamil’s extensive experience...

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company HighlightsDurable single agent activity observed with MT-6402, a PD-L1 targeting direct-cell kill agent, in heavily pre-treated patients with low PD-L1+ head and neck cancer who had progressed on multiple prior therapies including checkpoint and EGFR antibodies. Enrollment is on-going in the dose escalation study with MT-8421, a novel CTLA-4 targeting agent...

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million with leading life science investors Cash and equivalents of $56.6 million as of December 31, 2023 Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026 Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (Nasdaq:SABS), (“SAB” or “the company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of Type 1 diabetes (T1D), today announced its financial results for the fourth quarter of 2023...

Month: March 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice